477293-60-0

Usage

Uses

Used in Pharmaceutical Industry:
(2S, 4S)-4-Hydroxy-2-methyl-pyrrolidine-1-carboxylic acid tert-butyl ester is used as a building block for the synthesis of certain drugs, leveraging its unique structure to create novel therapeutic agents. Its chiral nature also makes it a potential candidate for the development of enantiomerically pure compounds, which are essential in the pharmaceutical field to ensure the desired biological activity and minimize side effects.
Used as a Chiral Auxiliary in Asymmetric Synthesis:
In the realm of organic chemistry, (2S, 4S)-4-Hydroxy-2-methyl-pyrrolidine-1-carboxylic acid tert-butyl ester serves as a chiral auxiliary, aiding in the asymmetric synthesis of complex molecules. Its stereochemistry helps guide the formation of specific enantiomers, which is crucial for the production of biologically active compounds with minimal side effects.
Used in the Development of New Materials:
(2S, 4S)-4-Hydroxy-2-methyl-pyrrolidine-1-carboxylic acid tert-butyl ester may also find applications in the development of new materials, such as chiral polymers or catalysts, due to its unique structural features and potential for functionalization.
Used as a Chemical Intermediate in Organic Synthesis:
Furthermore, (2S, 4S)-4-Hydroxy-2-methyl-pyrrolidine-1-carboxylic acid tert-butyl ester can be utilized as a chemical intermediate in various organic synthesis processes, enabling the creation of a wide range of chemical products with diverse applications across different industries.

Upstream product

• 477293-59-7 (2S,4S)-4-Formyloxy-2-methyl-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 114676-61-8 tert-butyl (2S,4R)-4-hydroxyl-2-methylpyrrolidine-1-carboxylate 
• 1123305-80-5 1,1-dimethylethyl (2S,4S)-4-{[(1,1-dimethylethyl)(dimethyl)silyl]oxy}-2-methyl-1-pyrrolidinecarboxylate 
• 791602-89-6 4-(tert-butyldimethylsilanyloxy)-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester 
• 924907-62-0 1,1-dimethylethyl (2R,4S)-4-{[(1,1-dimethylethyl)(dimethyl)silyl]oxy}-2-{[(methylsulfonyl)oxy]methyl}-1-pyrrolidinecarboxylate 
• 135042-17-0 (2R,4S)-1-tert-butyl 2-methyl 4-hydroxypyrrolidine-1,2-dicarboxylate 
• 178962-09-9 methyl (2R,4S)-4-hydroxypyrrolidine-2-carboxylate 
• 3398-22-9 trans-4-hydroxyproline 
• 134441-72-8 1,1-dimethylethyl (2R,4S)-4-{[(1,1-dimethylethyl)(dimethyl)silyl]oxy}-2-(hydroxymethyl)-1-pyrrolidinecarboxylate 

Downstream Products

• 1123307-53-8 2,5-dibromo-N-[(3R,5S)-1-cyano-5-methyl-3-pyrrolidinyl]benzenesulfonamide 
• 1123305-82-7 1,1-dimethylethyl (2S,4R)-4-{[(2,5-dibromophenyl)sulfonyl]amino}-2-methyl-1-pyrrolidinecarboxylate 
• 708274-46-8 1,1-dimethylethyl (2S,4R)-4-amino-2-methyl-1-pyrrolidinecarboxylate 
• 1123309-12-5 C₁₁H₁₄Br₂N₂O₂S 
• 477293-64-4 C₃₅H₄₇NO₃S 

Relevant academic research and scientific papers

HETEROCYCLE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONIST ACTIVITY

The present invention is related to a compound represented by formula (I), wherein X1, X2, X3, X4, X5, R5, R6, R7, R8, n, p, q, ring A and ring B are as described in the specification, or a

Discovery of novel cyanamide-based inhibitors of cathepsin C

The discovery of potent and selective cyanamide-based inhibitors of the cysteine protease cathepsin C is detailed. Optimization of the template with regard to plasma stability led to the identification of compound 17, a potent cathepsin C inhibitor with excellent selectivity over other cathepsins and potent in vivo activity in a cigarette smoke mouse model.

NOVEL CATHEPSIN C INHIBITORS AND THEIR USE

The invention is directed to compounds according to Formula (I) wherein R1, R2a, R2b, R2c, R3, and n are defined below, and to pharmaceutically-acceptable salts thereof. They are cathepsin C inhibitors and can be used in the treatment of diseases mediated

Synthesis and evaluation of novel pyrrolidinyl sordaricin derivatives as antifungal agents

N-Benzyl pyrrolidinyl sordaricin derivatives have been synthesized from cis-4-hydroxy-D-proline in a stereocontrolled manner. These compounds maintained moderate antifungal activity against several pathogenic fungal strains. Their MIC values against Candida albicans were in the range of 0.25-2 μg/mL.